- Home
- TSVT vs NLSP Comparison
TSVT vs NLSP Comparison
Compare TSVT & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- NLSP
- Stock Information
- Founded
- TSVT 2021
- NLSP 2015
- Country
- TSVT United States
- NLSP Switzerland
- Employees
- TSVT N/A
- NLSP N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- TSVT Health Care
- NLSP Health Care
- Exchange
- TSVT Nasdaq
- NLSP Nasdaq
- Market Cap
- TSVT 253.9M
- NLSP 243.8M
- IPO Year
- TSVT N/A
- NLSP 2021
- Fundamental
- Price
- TSVT $4.83
- NLSP $4.90
- Analyst Decision
- TSVT Buy
- NLSP
- Analyst Count
- TSVT 6
- NLSP 0
- Target Price
- TSVT $10.40
- NLSP N/A
- AVG Volume (30 Days)
- TSVT 344.9K
- NLSP 26.6K
- Earning Date
- TSVT 11-12-2024
- NLSP 10-11-2024
- Dividend Yield
- TSVT N/A
- NLSP N/A
- EPS Growth
- TSVT N/A
- NLSP N/A
- EPS
- TSVT N/A
- NLSP N/A
- Revenue
- TSVT $44,120,000.00
- NLSP N/A
- Revenue This Year
- TSVT N/A
- NLSP N/A
- Revenue Next Year
- TSVT $22.42
- NLSP N/A
- P/E Ratio
- TSVT N/A
- NLSP N/A
- Revenue Growth
- TSVT N/A
- NLSP N/A
- 52 Week Low
- TSVT $1.54
- NLSP $4.08
- 52 Week High
- TSVT $6.40
- NLSP $40.60
- Technical
- Relative Strength Index (RSI)
- TSVT 52.75
- NLSP 37.46
- Support Level
- TSVT $4.44
- NLSP $4.72
- Resistance Level
- TSVT $4.83
- NLSP $5.50
- Average True Range (ATR)
- TSVT 0.33
- NLSP 0.65
- MACD
- TSVT -0.00
- NLSP 0.02
- Stochastic Oscillator
- TSVT 56.86
- NLSP 28.47
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.